Kornimate/medical-research-clean huggingface dataset:
fibromyalgia and sleep disorder treatment

Conditions: Fibromyalgia; Sleep Disorder

Summary: this longitudinal study will investigate impact of improved sleep quality on chronic pain, fibromyalgia and how the disrupted sleep pattern alters the neuroenvironment.

the main aim of this study is to evaluate the interaction between pain and sleep, both directly by comparing outcome measures of pain and sleep, and out of one inflammatory perspective using proteomics analyzes. currently, there is a need for studies that highlight both the above-mentioned interaction and how the inflammatory response in the central nervous system as well as in the systemic circulation is involved. the cohort in existing study (fine study) is already being used to find associations between these, but as it is a cross-sectional study, the design cannot determinate the causality. the implementation of a longitudinal study where sleep is the single parameter that is modified would add an invaluable scientific basis for the assessment of this complex interplay. because fine study also has measurements of both systemic as central immunoactivity, the scientific value becomes very high, and can potentially be helpfull in understanding what happens to pain when sleep is affected, and which immune mediators that are relevant in that dynamic. if it turns out that the treatment of sleep disorders is effective from a pain perspective, it would in addition bring a whole new line of treatment options in fibromyalgia, and emphasize the importance of implementation a proper sleep analysis in the investigation phase for this patient group.

Eligibility criteria:
inclusion criteria: * fibromyalgia according to 1990 and 2016 acr (american college of rheumatology criteria) * included in fine study * sleep disorder exclusion criteria: * other autoimmune or neuroinflammatory diseases than fm. * other dominating pain conditions other than fm (e.g., severe pain due to osteoarthritis, disc herniations etc). * severe somatic or psychiatric diseases that would preclude participation or influence results (e.g., cancer, infectious diseases etc). * pregnancy. * inability to speak and understand swedish. * treatment with anticoagulants. * high intracranial pressure. * ongoing infections. * hemophilia.

Keywords: inflammation
juxtarenal aortic aneurysm

Conditions: Juxtarenal Aneurysms; Open Repair

Summary: all patients with a juxtarenal abdominal aortic aneurysm who underwent open aneurysm therapy between january 2010 and july 2020 were included retrospectively.


Eligibility criteria:
inclusion criteria: * patients with a juxtarenal aneurysm (defined as infrarenal neck \<10mm and clamping above at least one renal artery \[31592091\]) * open therapy with infrarenal (anschluss) * \>18 years exclusion criteria: * patients with an anastomosis above the renal arteries (e.g. including bypass to a renal artery) * patients with supravisceral clamping * patients with reconstruction of the aorta in the suprarenal area * patients with connective tissue diseases (e.g. marfan syndrome or ehler danlos syndrome) * post-dissection aneurysms * infected aneurysms * conversions after endovascular therapy * inflammatory aneurysms
satisfaction and recovery after trigger finger release

Conditions: Trigger Finger Disorder

Summary: trigger finger release is one of the most common procedures in hand surgery. however, little is known about the patient perceived outcome directly after surgery and the timespan to recovery of normal hand function.this study focuses on patient reported outcome scores within the first six weeks after surgery.

patients scheduled for release of trigger finger are assessed regarding the following outcome measures: 1. vas score for pain 2. vas score for finger movement 3. vas score for fréquence of triggering 4. hakir questionnaire (validated instrument for hand function in the swedish national hand registry) 5. quick-dash questionnaire. after surgery, the patients records the following outcomes: each day: 1,2,3 and records of pain medication details each week: 4,5 for 6 weeks

Eligibility criteria:
inclusion criteria: 1. trigger phenomenon and/or 2. tenderness volarly to mcp joint of affected finger/thumb 3. patient scheduled for trigger finger release 4. signed informed consent exclusion criteria: 1. concomitant hand injuries/ conditions 2. multiple fingers/thumbs to be treated 3. unable to read/understand instructions in swedish
efficacy of treatment with berberine to maintain remission in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the research aim to find out whether berberine can reduce the annual recurrence rate of ulcerative colitis in remission. a total of 238 patients with ulcerative colitis in remission will be randomly divided into two groups.one will receive regular treatment,and the other group will receive extra oral berberine 300 mg three times daily for a year. the end of the study for every patient is disease recurrence(mayo clinic score of 3 points or more ). the primary analysis is annual recurrence rate, and both endoscopy and mayo clinic disease activity index scores at the baseline and final assessments.


Eligibility criteria:
inclusion criteria: 1. diagnosis with ulcerative colitis(according to the second european evidence-based consensus on the diagnosis and management of ulcerative colitis); 2. disease remission of ulcerative colitis(a total mayo clinic score of 2 points or less and an endoscopic score of 1 point or less); 3. diagnosis of moderate or severe ulcerative colitis within 3 months(a total mayo clinic score of 6-12 points) exclusion criteria: 1. prior bowel resection surgery; 2. women who are planning or actual pregnancy or lactation during study period; 3. patients allergic to berberine; 4. history of disease that would interfere with their participation in the trial, including malignant diseases, bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, and mental or emotional disorder; 5. take the following treatment: * unstable dose of 5-asa drugs (oral and/or rectal route) within 14 days prior to screening; * unstable dose of any immunomodulating/suppressive agents and any anti-tnf therapy within 3 months prior to screening; * traditional chinese medicine for the treatment of uc (any pharmaceutical form) within 7 days prior to screening.

Keywords: ulcerative colitis berberine
adalimumab in combination with methotrexate vs methotrexate alone in early rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the effectiveness of adalimumab in combination with methotrexate compared to methotrexate alone on work disability in subjects with early rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * subject is age 18 or older and in good health (investigator discretion) with a recent stable medical history * subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised acr criteria * subject must be in paid employment * subject has self-reported work impairment since onset of symptoms exclusion criteria: * a subject has chronic arthritis diagnosed before age 16 years. * subject has been on preceding treatment with methotrexate subject unable to withdraw from current dmards * subject has preceding treatment with any biological tnf antagonist * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study * female subject who is pregnant or breast-feeding or considering becoming pregnant
characterization of myeloproliferative neoplasia with a mutated idh, srsf2 or sf3b1 allele (carpediem)

Conditions: Myeloproliferative Disorders

Summary: retrospective study assessing the impact of idh1/2, srsf2 or sf3b1 mutations on event free survival of mpn patients

patients with a diagnosis of mpn and a mutation of idh1/2, srsf2 or sf3b1 will be included. clinical and biological characterisation at diagnosis, as well as evlution will be recorded. event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).

Eligibility criteria:
inclusion criteria: * patients with mpn diagnosis * mutation in idh1/2, srsf2 or sf3b1 exclusion criteria: * unable to consent
obstructive sleep apnea treatment to improve cardiac rehabilitation

Conditions: Obstructive Sleep Apnea; Coronary Heart Disease

Summary: this is a randomized clinical trial in u.s. veterans to evaluate the impact of treatment for obstructive sleep apnea (osa) on the effectiveness of cardiac rehabilitation, including impact on exercise capacity, disability, and quality of life.

obstructive sleep apnea (osa) is a highly prevalent condition in patients with coronary heart disease and is associated with impaired exercise performance, functional limitation and reduced health-related quality of life. the investigators hypothesize that identification and treatment of osa in patients undergoing cardiac rehabilitation will improve the response to rehabilitation. the proposed study will test this hypothesis using a parallel group, randomized, clinical trial comparing osa treatment with continuous positive airway pressure (cpap) to an educational control group in patients undergoing cardiac rehabilitation who screen positive for previously undiagnosed osa.

Eligibility criteria:
inclusion criteria: * veterans referred for cardiac rehabilitation at the va boston healthcare system. * moderate to severe osa (ahi \>15) on home sleep testing. exclusion criteria: * dangerous levels of sleepiness (epworth sleepiness scale score \>16 or a report of falling asleep at the wheel of a car within the past 2 years). * physical limitation precluding exercise testing.

Keywords: obstructive sleep apnea coronary heart disease cardiac rehabilitation cardiopulmonary exercise testing
study of the prevalence of iron deficiency in patients with chronic renal failure but non-dialysis (carenfer irc-nd)

Conditions: Chronic Kidney Diseases

Summary: despite its known prevalence, a recent study conducted with prof. cacoub (unpublished) on the national health insurance database showed that iron deficiency was a poorly diagnosed and poorly treated comorbidity. in patients with chronic kidney disease but non-dialysis, the determination of ferritinemia and transferrin saturation factoris performed in only 30% and 10% of cases whereas they should be performed routinely in inflammatory situations and in case of anemia (has 2011, kdigo 2012). the objective of this study is to obtain updated data on the prevalence of iron deficiency in france in patients with ckd-nd, applying the international recommendations and those of the french health high authority (determination of ferritinemia and transferrin saturation factor).


Eligibility criteria:
inclusion criteria: * patient, male or female, over 18 years of age; * patient present at the hospital on the day of the study (traditional hospitalization, week hospital, day hospital, or in consultation with ckd-nd); * diagnosis of ckd-nd (glomerular filtration rate (gfr) \> 15 ml/min/1.73 m²) * patient with signed consent exclusion criteria: * protected patient: major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision; * pregnant or breastfeeding woman; * patient with dialysis
montelukast for postinfectious cough

Conditions: Cough

Summary: cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. subacute has a 3\~8 weeks course of disease. its main etiology is postinfectious cough, which is mostly secondary to viral infection.considering its overexpression in postinfectious patient, cysteinyl leukotriene (cyslts) plays a role in gathering eosinophils to respiratory. the level of feno has a significant correlation with inflammatory airway eosinophils. while cyslts overexpressed in vivo, the level of feno may increase. montelukast, as cyslts-receptor-1 antagonists， plays a role of controlling airway inflammation and decrease airway high activity by suppressing the biological activity of cyslts. it is effective in theory to therapy sub-acute cough by montelukast, to short the course and to relieve cough symptoms as soon as possible. the aim is to research whether feno can be used as a biomarker to optimized treatment regimen of sub-acute cough.

patients in electrical treatment arm were given montelukast sodium tablets (p.o., 10mg, q.d.) . patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.).all treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Eligibility criteria:
inclusion criteria: * cough is the main or only clinical symptom and was persistent for 3-8 weeks * chest x-ray reveals no noticeable pathological changes * 18 year old, regardless of gender and ethical background * not taking angiotensin-converting enzyme inhibitor * patients must join the programme voluntarily and are able to attend examination and follow-up sessions exclusion criteria: * patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial respiratory tract infections * patients diagnosed with severe reportorial disease of other severe systemic disease * patients who are allergic to any drugs to be tested * patients who are non-cooperative during examination sessions or other steps of the trial * patients who are not able to or refuse to sign consent
new indications for ultrasound in the staging of cervical cancer

Conditions: Cervical Cancer

Summary: the purpose is to investigate and evaluate two new diagnostic methods using ultrasound in the staging of cervical cancer. 1. 3-d-ultrasound of the tumour to estimate its volume and local spread 2. fusion of pet/ct and ultrasound to evaluate and biopsy lymph nodes.


Eligibility criteria:
inclusion criteria: * cervical cancer, * pet/ct pos. lymph nodes, * patients over 18 years old exclusion criteria: * pregnancy, * lactating, * diabetic
coenzyme q10 role in prevention of contrast induced nephropathy in acute coronary syndrome patients.

Conditions: Contrast-induced Nephropathy

Summary: in this study the investigators aim to study the effect of supplementation of coq10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme q10.

Eligibility criteria:
inclusion criteria: * patients who are 18 years or older. * st-elevation myocardial infarction (stemi). * non st-elevation myocardial infarction( nstemi). * unstable angina (ua) exclusion criteria: * renal transplant patients. * preoperative bleeding . * intraoperative bleeding or hypotension. * patients taking any nephrotoxic medications
retrospective analysis of pet brain imaging in chronic cancer pain

Conditions: Cancer Pain

Summary: cancer pain deteriorated in quality of life and related with numerous psychosocial problems. over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. the 18f-fluoro-2-deoxyglucose (fdg) positron emission tomography/computed tomography (pet/ct) images can provide quantitative results in clinical oncology. as a functional neuroimaging, the pet evidently provided anatomical activated regions, size, and spatial extent information. in this retrospective study, we use fdg-pet to investigate changes concerning the glucose metabolism in the brain with or without cancer pain.


Eligibility criteria:
inclusion criteria: * cancer patient exclusion criteria: * no brain metastasis
mechanism of decompensation evaluation - aortic stenosis

Conditions: Aortic Stenosis; Myocardial Fibrosis; Left Ventricular Hypertrophy

Summary: aortic stenosis is the most common heart valve disease requiring intervention in high income countries. it is characterised by progressive valvular thickening, and restriction as well is hypertrophy and fibrosis of the left ventricle in response to pressure overload. the pathological processes in the left ventricle that ultimately result in heart failure and death are incompletely understood. further elucidation of these processes and how they correlate with novel blood biomarkers may help us design new treatments and optimise the timing of surgical intervention. in brief, recruited patients with severe aortic stenosis and scheduled to undergo valve replacement surgery will be invited for some simple tests (blood sampling, ecg, echocardiogram). a septal myocardial biopsy will be taken at the time of surgery and the disease valve retained. these will be examined histologically and pathological changes compared with results obtained from ecg, echocardiogram and blood tests.


Eligibility criteria:
* inclusion criteria (aortic stenosis group): * age over 18 * severe aortic stenosis with planned aortic valve replacement inclusion criteria (control group): * age over 18 * planned non-aortic valve cardiac or elective ascending aorta surgery exclusion criteria (aortic stenosis group): * coexistent severe aortic or mitral regurgitation * coexistent mitral stenosis greater than mild in severity * acute valvular heart disease (e.g. acute mitral regurgitation or endocarditis) * acute pulmonary oedema or cardiogenic shock * coexistent hypertrophic cardiomyopathy * unable to give informed consent exclusion criteria (control group): * significant aortic valve disease (mild aortic stenosis / regurgitation or greater) * acute valvular heart disease (e.g. acute mitral regurgitation or endocarditis) * acute pulmonary oedema or cardiogenic shock * coexistent hypertrophic cardiomyopathy * unable to give informed consent

Keywords: troponin
the effect of progressive muscle relaxation on abdominal pain and distension in colonoscopy patients.

Conditions: Abdominal Pain

Summary: patients undergoing colonoscopy were divided into progressive relaxation exercises and control groups. pretest and posttest abdominal pain and distention scores of the patients were determined after colonoscopy.


Eligibility criteria:
inclusion criteria: * patients undergoing colonoscopy * those who do not have communication problems, * after the colonoscopy procedure, the abdominal pain score is evaluated by vas and is 4 or higher, * evaluation of the distension score of 4 and above with vas after the colonoscopy procedure, * be 18 years old or older. exclusion criteria: * being a hospitalized patient undergoing colonoscopy, * be younger than 18 years old * to have used complementary and alternative methods during the research, * any physical problem that may prevent you from doing the exercises, * having a cognitive illness * refusing to participate in the research, * failing to complete surveys.

Keywords: colonoscopy abdominal pain nursing relaxation exercise
carboxyamidotriazole in treating patients with advanced kidney cancer

Conditions: Kidney Cancer

Summary: rationale: carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor. purpose: phase ii trial to study the effectiveness of carboxyamidotriazole in treating patients who have advanced kidney cancer that has not responded to biological therapy.

objectives: i. determine the disease free progression at 6 months in patients with locally recurrent or metastatic renal cell cancer (refractory to immunotherapy) treated with carboxyamidotriazole. ii. evaluate the progression free survival rate and response rate in these patients on this regimen. iii. evaluate the toxic effect of this regimen on these patients. outline: patients receive oral carboxyamidotriazole daily. treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. patients with stable disease may discontinue therapy after 6 courses. patients are followed every 3 months for 2 years, every 6 months for 3 years, and every 12 months thereafter until death. projected accrual: a total of 55 patients will be accrued for this study within 20 months.

Eligibility criteria:
disease characteristics: histologically proven advanced renal cell cancer locally recurrent or metastatic lesions not amenable to current resection progressive disease defined as 25% increase from last measurement or new lesions bidimensionally measurable disease no brain metastases patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: wbc greater than 3,000/mm3 or absolute neutrophil count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 1.5 mg/dl sgot and/or sgpt less than 2 times upper limit of normal renal: creatinine less than 2.0 mg/dl other: not pregnant or nursing fertile patients must use effective contraception no other serious medical illness or active infection that would preclude chemotherapy compliance no other prior malignancy unless curatively treated and disease free for the past 5 years prior concurrent therapy: biologic therapy: at least 4 weeks since prior biologic therapy at least 1 (but no more than 2) prior biologic regimen(s) (i.e., interleukin-2, interferon alfa, or combination) and recovered regimen defined as at least 8 weeks of treatment prior sargramostim allowed chemotherapy: no prior chemotherapy endocrine therapy: at least 4 weeks since prior hormonal therapy (i.e., megestrol or tamoxifen) and recovered radiotherapy: no prior radiotherapy to study lesions at least 4 weeks since prior radiotherapy and recovered no concurrent palliative radiotherapy surgery: prior nephrectomy allowed recovered from any recent surgery

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer
weight management & wellness for people with psychiatric disabilities

Conditions: Obesity; Mental Illness

Summary: the purpose of this study is to conduct a randomized controlled trial to test the effectiveness of an intervention called nutrition and exercise for wellness and recovery (new-r) in promoting healthy eating and increased physical activity for better weight management among psychiatric outpatients.

weight management is a serious issue for individuals with mental health conditions, especially those who are taking psychiatric medications. the latest estimates are that over half of individuals receiving community mental health services are overweight or obese. this project's objective is to conduct a randomized controlled trial to test the effectiveness of an intervention called nutrition and exercise for wellness and recovery (new-r) in promoting healthy eating and increased physical activity for better weight management among psychiatric outpatients living and working in the community. it is an 8-week, recovery-oriented intervention that is co-led by a trained health educator and a certified mental health peer specialist. the study will take place at the uic department of psychiatry in chicago. research participants will be recruited from the department's outpatient clinics and other community programs, and randomly assigned to receive new-r along with services as usual or services as usual alone.

Eligibility criteria:
inclusion criteria: * diagnosis with a mental health disorder * patient of outpatient program * age 18 or older * being overweight or obese defined as bmi\>=25 * ability to understand spoken english exclusion criteria: * residing in a nursing home * cardiac event in past 6 months * past episode of anorexia or bulimia * pregnancy * diagnosis with a terminal illness expected to result in death within 1 year * active alcohol or substance abuse or dependence * inability to provide informed consent due to diagnosis of dementia or cognitive impairment * inability to understand spoken english

Keywords: obesity, weight management, serious mental illness